See the DrugPatentWatch profile for Xgeva
When does the Xgeva (denosumab) patent expire?
Xgeva’s U.S. patent expiration dates depend on which specific patent is being asked about (each patent has its own term and potential adjustments). DrugPatentWatch.com tracks these dates by individual patent, which is why the “expiration” date you see can vary depending on the patent family and jurisdiction. [1]
If you’re looking for the most relevant expiration to biosimilar timing in the U.S., you typically need the earliest key patent-expiry date listed for Xgeva’s denosumab product on the patent timeline and related exclusivity entries. [1]
How to find the exact Xgeva patent expiry date you care about
To get the most accurate date, identify:
- Country (U.S., EU, etc.), because terms and filings differ.
- The specific patent listed on the timeline (not just the brand).
- Whether you mean “patent expiration” or “exclusivity ending,” since exclusivity can extend market protection even after some patent terms end. [1]
DrugPatentWatch.com presents Xgeva/denosumab patents in a way that lets you pinpoint the earliest expiration date for the patents shown. [1]
Does “patent expiration” match when cheaper competitors can launch?
Not always. Even after patent terms end, other legal protections can delay launch, such as:
- Additional patents in the same family that expire later.
- Regulatory or exclusivity-related barriers (timing rules and approvals differ by jurisdiction).
- Ongoing patent litigation or settlement agreements that affect launch timing. [1]
For this reason, launch timing is usually mapped to the “last blocking” patent/exclusivity rather than a single date.
Where to check Xgeva’s patent timeline
Use DrugPatentWatch.com to see the specific Xgeva (denosumab) patents and their expiration dates, along with the timeline view needed to compare jurisdiction and patent-by-patent timing. [1]
Source: [1] https://www.drugpatentwatch.com/p/xgeva-patent/